The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutationsRIELY, Gregory J.Lung cancer. 2008, Vol 60, issn 0169-5002, S19-S22, SUP2Conference Paper

Update on epidermal growth factor receptor mutations in non-small cell lung cancerRIELY, Gregory J; POLITI, Katerina A; MILLER, Vincent A et al.Clinical cancer research. 2006, Vol 12, Num 24, pp 7232-7241, issn 1078-0432, 10 p.Article

A rheostatic mechanism for T-cell inhibition based on elevation of activation thresholdsRACHMILEWITZ, Jacob; RIELY, Gregory J; HUANG, Jui-Han et al.Blood. 2001, Vol 98, Num 13, pp 3727-3732, issn 0006-4971Article

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to ErlotinibJANJIGIAN, Yelena Y; AZZOLI, Christopher G; RIELY, Gregory J et al.Clinical cancer research (Print). 2011, Vol 17, Num 8, pp 2521-2527, issn 1078-0432, 7 p.Article

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung AdenocarcinomaBEAN, James; RIELY, Gregory J; BALAK, Marissa et al.Clinical cancer research (Print). 2008, Vol 14, Num 22, pp 7519-7525, issn 1078-0432, 7 p.Article

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung AdenocarcinomaRIELY, Gregory J; KRIS, Mark G; MILLER, Vincent A et al.Clinical cancer research (Print). 2008, Vol 14, Num 18, pp 5731-5734, issn 1078-0432, 4 p.Article

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusRIELY, Gregory J; KRIS, Mark G; MILLER, Vincent A et al.Clinical cancer research. 2007, Vol 13, Num 17, pp 5150-5155, issn 1078-0432, 6 p.Article

Ceritinib in ALK-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; KIM, Dong-Wan; RIELY, Gregory J et al.The New England journal of medicine. 2014, Vol 370, Num 13, pp 1189-1197, issn 0028-4793, 9 p.Article

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferaseZAUDERER, Marjorie G; DRILON, Alex; HOLODNY, Andrei I et al.Lung cancer. 2014, Vol 86, Num 2, pp 237-240, issn 0169-5002, 4 p.Article

New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical TrialsTRAVIS, William D; BRAMBILLA, Elisabeth; RIELY, Gregory J et al.Journal of clinical oncology. 2013, Vol 31, Num 8, pp 992-1001, issn 0732-183X, 10 p.Article

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M MutationOXNARD, Geoffrey R; ARCILA, Maria E; SIMA, Camelia S et al.Clinical cancer research (Print). 2011, Vol 17, Num 6, pp 1616-1622, issn 1078-0432, 7 p.Article

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to ErlotinibMILLER, Vincent A; RIELY, Gregory J; HERBST, Roy S et al.Journal of clinical oncology. 2008, Vol 26, Num 9, pp 1472-1478, issn 0732-183X, 7 p.Article

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor : Mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsBALAK, Marissa N; YIXUAN GONG; LADANYI, Marc et al.Clinical cancer research. 2006, Vol 12, Num 21, pp 6494-6501, issn 1078-0432, 8 p.Article

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based AssayARCILA, Maria E; OXNARD, Geoffrey R; NAFA, Khedoudja et al.Clinical cancer research (Print). 2011, Vol 17, Num 5, pp 1169-1180, issn 1078-0432, 12 p.Article

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical TrialsJACKMAN, David M; MILLER, Vincent A; CIOFFREDI, Leigh-Anne et al.Clinical cancer research (Print). 2009, Vol 15, Num 16, pp 5267-5273, issn 1078-0432, 7 p.Article

Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non-Small-Cell Lung CancerRIELY, Gregory J; RIZVI, Naiyer A; SESHAN, Venkatraman E et al.Journal of clinical oncology. 2009, Vol 27, Num 2, pp 264-270, issn 0732-183X, 7 p.Article

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung CancerRIZVI, Naiyer A; RIELY, Gregory J; KRIS, Mark G et al.Journal of clinical oncology. 2008, Vol 26, Num 4, pp 639-643, issn 0732-183X, 5 p.Article

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon19 and exon 21 mutations treated with gefitinib or erlotinibRIELY, Gregory J; PAO, William; PHAM, Duykhanh et al.Clinical cancer research. 2006, Vol 12, Num 3, pp 839-844, issn 1078-0432, 6 p., 1Article

Crizotinib in ROS1-Rearranged Non―Small-Cell Lung CancerSHAW, Alice T; OU, Sai-Hong I; DOEBELE, Robert C et al.The New England journal of medicine. 2014, Vol 371, Num 21, pp 1963-1971, issn 0028-4793, 9 p.Article

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancersYU, Helena A; ARCILA, Maria E; REKHTMAN, Natasha et al.Clinical cancer research (Print). 2013, Vol 19, Num 8, pp 2240-2247, issn 1078-0432, 8 p.Article

Driver Mutations Determine Survival in Smokers and Never-Smokers With Stage IIIB/IV Lung AdenocarcinomasPAIK, Paul K; JOHNSON, Melissa L; D'ANGELO, Sandra P et al.Cancer. 2012, Vol 118, Num 23, pp 5840-5847, issn 0008-543X, 8 p.Article

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersDOGAN, Snjezana; RONGLAI SHEN; LADANYI, Marc et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6169-6177, issn 1078-0432, 9 p.Article

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or GefitinibOXNARD, Geoffrey R; JANJIGIAN, Yelena Y; MILLER, Vincent A et al.Clinical cancer research (Print). 2011, Vol 17, Num 19, pp 6322-6328, issn 1078-0432, 7 p.Article

Comparison of patterns of relapse in thymic carcinoma and thymoma. DiscussionHUANG, James; RIZK, Nabil P; HANDY, John et al.Journal of thoracic and cardiovascular surgery (Print). 2009, Vol 138, Num 1, pp 26-31, issn 0022-5223, 6 p.Article

Induction Chemoradiotherapy Followed by Resection for Locally Advanced Masaoka Stage III and IVA Thymic Tumors. CommentaryHUANG, James; RIELY, Gregory J; ROSENZWEIG, Kenneth E et al.The Annals of thoracic surgery. 2008, Vol 85, Num 2, issn 0003-4975, 365-367, 385-389 [8 p.]Article